[Illustrations] 2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms
by Oscar Wu
2026 Oncology crossroads divided into cytotoxic regimens and smart chemotherapy. (Design: Oscar Wu)
In the 2026 “clearing year” environment that is forcing AI platforms and radiopharma supply chains to prove themselves, antibody-drug conjugates (ADCs) are being positioned as …
GO Prime with only $1.49 now
LATEST
Aeroméxico Directors and Executives Acquire Company Shares Through Individual Investment Decisions
2026-03-17
Fury Gold Mines Reports 11.74 g/t Gold Over 6.63 Meters in Eau Claire Phase 2 Drilling Campaign
2026-03-17
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California






